8-K: Evoke Pharma Reports Record Third Quarter Revenue Driven by Strong GIMOTI Sales

Evoke Pharma announced its highest ever quarterly revenue of $2.7 million for GIMOTI in Q3 2024, marking a 70% year-over-year increase.

Summary

• Evoke Pharma reported a significant increase in revenue for the third quarter of 2024, reaching $2.7 million, a 70% increase compared to the same period last year.
• The company saw a 45% year-over-year increase in cumulative prescribers and a 52% year-over-year increase in prescription fills.
• Real-world data presented at ACG 2024 showed that GIMOTI significantly improved outcomes for patients on GLP-1 therapy.
• The company's net loss for the quarter was $1.3 million, or $0.94 per share, compared to a net loss of $1.7 million, or $6.08 per share, in the third quarter of 2023.
• Evoke has revised its 2024 revenue guidance to $9.5-10.0 million, still anticipating almost a doubling from the previous year.
• As of September 30, 2024, the company had $11.3 million in cash and cash equivalents, and raised an additional $3.5 million in October through warrant exercises.
• The company expects its current cash to fund operations into the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased prescriber and prescription rates, and positive real-world data. The company's financial position is also strengthened by recent warrant exercises. However, the revised revenue guidance and ongoing losses temper the overall sentiment slightly.

Positives

• GIMOTI sales are showing strong growth, with a 70% year-over-year increase in net product sales.
• There is significant growth in both the number of prescribers and prescription fills.
• Real-world data supports GIMOTI's effectiveness, particularly for patients on GLP-1 therapy.
• The company has expanded patient access through new pharmacy partnerships and improved insurance reimbursement rates.
• The company has a robust balance sheet with sufficient cash to fund operations into the fourth quarter of 2025.
• The net loss per share has improved significantly compared to the same quarter last year.

Negatives

• The company is still operating at a loss, with a net loss of $1.3 million for the quarter.
• Selling, general, and administrative expenses increased by $0.7 million compared to the same quarter last year.
• The 2024 revenue guidance has been revised down to $9.5-10.0 million from $11-12 million.

Risks

• The company's ability to achieve its revised 2024 revenue guidance is dependent on various factors, including market demand, reimbursements, and external factors like the macroeconomic environment.
• The company is dependent on the success of GIMOTI and faces risks related to its manufacturing and intellectual property protection.
• There are potential risks associated with inadequate efficacy or unexpected adverse side effects of GIMOTI.
• The company may need to obtain additional financing in the future to support its operations.

Future Outlook

Evoke Pharma anticipates its current cash on hand will fund its operations into the fourth quarter of 2025 and has revised its 2024 revenue guidance to $9.5-10.0 million.

Management Comments

• Matt DOnofrio, CEO of Evoke Pharma, stated that they are encouraged by the strong year-over-year growth metrics for GIMOTI and that this was the highest quarter of revenue on record.
• Chris Quesenberry, Chief Commercial Officer of GIMOTI, highlighted the positive feedback from patients and providers and the company's mission to challenge the notion that gastroparesis patients are doing fine with current treatment options.

Industry Context

The announcement highlights the growing demand for non-oral treatments for diabetic gastroparesis, particularly as an alternative to traditional oral medications. The data presented at ACG 2024 positions GIMOTI as a promising option for patients on GLP-1 therapy, a growing market segment.

Comparison to Industry Standards

• While specific competitor data is not provided, the 70% year-over-year revenue growth for GIMOTI is significant in the pharmaceutical industry, where growth rates are often more modest.
• The company's focus on a nasal spray formulation of metoclopramide differentiates it from companies offering only oral or injectable options.
• The real-world data presented at ACG 2024, which won awards, suggests that GIMOTI is performing well compared to other treatments for diabetic gastroparesis.
• The company's ability to secure reimbursement from Medicare and Medicaid programs is a positive sign for its market penetration and accessibility.

Management Changes

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial position positively.
• Patients will benefit from increased access to GIMOTI and its demonstrated effectiveness.
• Healthcare providers will have a more effective treatment option for diabetic gastroparesis.
• Employees may experience increased job security due to the company's improved financial performance.

Next Steps

• The company will continue to focus on expanding access to GIMOTI and engaging more prescribers.
• Evoke will continue to monitor market demand, reimbursements, and external factors to achieve its revised 2024 revenue guidance.
• The company will continue to present data supporting the efficacy of GIMOTI.

Key Dates

Keywords

GIMOTI, Evoke Pharma, Diabetic Gastroparesis, Metoclopramide, Nasal Spray, Pharmaceutical, Revenue, Prescriptions, GLP-1 Therapy, Healthcare, Financial Results